ClinicalTrials.gg
CompletedNCT04641871Updated Jun 26, 2024

Sym021 in Combination With Either Sym022 or Sym023 or Sym023 and Irinotecan in Patients With Recurrent Advanced Selected Solid Tumor Malignancies

A Phase 1 interventional study of Sym021 and Sym022 in Metastatic Cancer and Solid Tumor, sponsored by Symphogen A/S. Completed at 17 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-06-26.

Sponsored by Symphogen A/S · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was Jun 2024, 2 years 5 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
78
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 2,057 studies in Neoplasm Metastasis with a site in United States — 344 open to participants now, 544 under way, 58 of them phase 3. Neoplasm Metastasis · United States.

Enrollment
636th of 1,866
78 · median 43
Started
2020
with 88 others
Phase 1
710 of 2,057
127 open now
Registered
1,466th of 2,057
by date

Among the 2,057 studies in Neoplasm Metastasis with a site in United States, this one is the 636th largest by enrollment of the 1,866 interventional ones that give a count, is one of 89 that started in 2020, is one of 710 in phase 1, and was the 1,466th registered.

Neoplasm Metastasis

4,052 studies on the registry are indexed under Neoplasm Metastasis; 891 are open to participants now.

Browse Neoplasm Metastasis studies →

Open to participants now

344 of the 2,057 studies in Neoplasm Metastasis with a site in United States are open now. Recruiting first, the newest first:

339 more — sign in →

All 344 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 692 Neoplasm Metastasis studies recruiting now, 539 (78%) set no upper age limit and 96 (14%) stop at 75 or younger; 47 take children under 18; 18 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,057 studies in Neoplasm Metastasis with a site in United States, or all of them as a file.
02

Study summary

The study will evaluate the preliminary efficacy of 3 combinations (Sym021+Sym022, Sym021+Sym023 and Sym021+Sym023+irinotecan) in patients with biliary tract carcinomas (BTC) and with esophageal squamous cell carcinoma (ESCC) by assessing overall response rates (ORRs) per Investigator assessment using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 The study will also evaluate the safety and tolerability profile of the 3 combinations

Read the detailed description

The study will evaluate safety and efficacy in patients with:

  • Biliary tract carcinomas patients who have progressed on one prior line of gemcitabine and platinum-based chemotherapy in the metastatic setting.
  • Esophageal squamous cell carcinoma patients who have progressed on one prior line of platinum-based chemotherapy in the metastatic setting.

The trial is set up as 3 sub-studies.

  • Sub-study 1 includes biliary tract carcinoma patients and is composed of 2 investigational combination treatment arms (Sym021+Sym022 [Arm A] and Sym021+Sym023 [Arm B]).
  • Sub-study 2, includes biliary tract carcinoma patients and is composed of one investigational combination treatment arm:Sym021+Sym023+irinotecan. A safety lead- in phase is included to assess tolerability of the combination. A Study Safety Team will review clinical and laboratory safety data and will make decisions regarding the continued enrollment after the safety lead-in phase.
  • Sub-Study 3, includes esophageal squamous cell carcinoma patients and is composed of one investigational combination treatment arm: Sym021+Sym023+irinotecan. Dose of irinotecan in this arm will be selected based upon the safety lead in in sub-study 2 period.

August 2021 : Based upon results from a recent per protocol Interim Analysis (IA) it is has been decided as of 3rd of August 2021 to stop further enrollment into Sub-study 1 Arm A (Sym021+Sym022). Future patients will be allocated to either Sub-study 1 Arm B (Sym021+Sym023) or Sub-study 2 (Sym021+Sym023+irinotecan).

03

Conditions studied

  • Metastatic Cancer
  • Solid Tumor

Keywords

  • Locally advanced/unresectable
  • Metastatic solid tumor
  • Anti-PD-1
  • PD-1
  • PD1
  • Anti-TIM-3
  • TIM-3
  • TIM3
  • Cholangiocarcinoma
  • CCA
  • Biliary Tract Carcinomas
  • Gallbladder
  • Esophageal Squamous Cell Carcinoma
  • ESCC
  • Irinotecan
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

For Sub-study 1 and 2:

  • Patients with locally advanced or biliary tract carcinoma including adenocarcinoma of the intra- and/or extra-hepatic bile ducts and gallbladder carcinoma. Patients with ampullary cancers are excluded.
  • Patients must only have received and progressed on or be intolerant of gemcitabine and platinum-based chemotherapy in metastatic/advanced setting and should not have received prior anti-PD-(L)1 therapy. Patients with known fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement, or isocitrate dehydrogenase 1 (IDH1) mutation will be excluded. Prior anti-PD-(L)1 therapy may be allowed during the trial if regulatory approval for such therapy is obtained while this trial is enrolling.

For Sub-study 3:

  • Patients with with locally advanced or metastatic esophageal squamous cell carcinoma
  • Patients must only have received and progressed on or be intolerant of first-line platinum-based chemotherapy in metastatic/advanced setting and should have received prior anti-PD-(L)1 therapy. Patients with mixed adenosquamous histology cancers are excluded.

For all Sub-studies :

  • Patients with according to v1.1
  • Patients with an PS of 0 or 1, and anticipated of ≥3 months
  • Patients must have adequate organ function as indicated by laboratory values
  • Adequate required as appropriate

Exclusion criteria

Exclusion Criteria:

  • Patients with central nervous system (CNS) , untreated or unstable
  • Patients with significant cardiovascular disease
  • Patients with

    1. Active thrombosis, or a history of deep vein thrombosis or pulmonary embolism, within 4 weeks prior to the first study drug dose
    2. Active uncontrolled bleeding or a known bleeding diathesis
  • Patients with a significant pulmonary disease or condition
  • Patients with a current or recent (within 6 months) significant gastrointestinal disease or condition
  • Patients with Gilbert's syndrome or patients with UGT1A1*28 homozygosity (also known as UGT1A1 7/7 genotype)
  • Patients with a significant ocular disease or condition
  • Patients with an active, known or suspected disease
  • Patients with any other serious/active/uncontrolled infection
  • Patients with a history of organ transplantation
  • Patients with (HIV) (HIV 1/2 antibodies) or active infection with virus or virus
  • Prior therapy with irinotecan
  • For Sub-study 1 and Sub-study 2: Anti-PD-(L)1, anti -LAG-3* or anti-TIM-3 containing regimen, or combination with any other systemic or localized therapy or any other immuno-oncology (IO) therapies.
  • For Sub-study 3: Anti-TIM-3 containing regimen, or combination with any other systemic or localized therapy or any other IO therapies (other than anti-PD-(L)1 agents).
  • Patients must not be on warfarin, if they have a history of acute immune-related thrombocytopenia; patients must not be on strong cytochrome P450 (CYP) 3A4 inducers, strong inhibitors, or strong UGT1A1 inhibitors.
  • Patients with a known or suspected to any of the of formulated study drug
  • Patients with unresolved >Grade 1 toxicity associated with any prior antineoplastic therapy
  • Sub-study 1 and Sub-study 2: Patients with known FGFR2 fusion or rearrangement, or IDH1 mutation.
  • For Sub-study 3: Patients with a history of significant toxicities associated with previous administration of that necessitated permanent discontinuation of that therapy.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
78 participants (actual)

Study arms

  • Experimental
    Sym021+Sym022 [ARM A] for BTC patients

    Sym021 will be infused over approximately 30 minutes (+10 minutes), followed by a 30-minute post-dosing interval before infusion of Sym022 over approximately 30 minutes (+10 minutes). The duration of each infusion may be extended by 30 minutes, or longer, if indicated.

    Drug: Sym021 · Drug: Sym022

  • Experimental
    Sym021+Sym023 [ARM B] for BTC patients

    Sym021 will be infused over approximately 30 minutes (+10 minutes), followed by a 30-minute post-dosing interval before infusion of Sym023 over approximately 30 minutes (+10 minutes). The duration of each infusion may be extended by 30 minutes, or longer, if indicated.

    Drug: Sym021 · Drug: Sym023

  • Experimental
    Sym021+Sym023+irrinotecan for BTC patients

    Sym021 will be infused over approximately 30 minutes (+10 minutes), followed by a 30-minute post-dosing interval before infusion of Sym023 over approximately 30 minutes (+10 minutes). The duration of each infusion may be extended by 30 minutes, or longer, if indicated. After another 30-minute post-dosing interval, irinotecan will be infused over 90 minutes.

    Drug: Sym021 · Drug: Sym023 · Drug: Irinotecan Hydrochloride

  • Experimental
    Sym021+Sym023+irrinotecan for ESCC patients

    Sym021 will be infused over approximately 30 minutes (+10 minutes), followed by a 30-minute post-dosing interval before infusion of Sym023 over approximately 30 minutes (+10 minutes). The duration of each infusion may be extended by 30 minutes, or longer, if indicated. After another 30-minute post-dosing interval, irinotecan will be infused over 90 minutes.

    Drug: Sym021 · Drug: Sym023 · Drug: Irinotecan Hydrochloride

Interventions

  • DrugSym021

    IV infusion over 30 minutes on day 1 and 15 of each cycle.

    Also known as: Anti-PD-1

  • DrugSym022

    IV infusion over 30 minutes on day 1 and 15 of each cycle.

    Also known as: Anti-LAG-3

  • DrugSym023

    IV infusion over 30 minutes on day 1 and 15 of each cycle.

    Also known as: Anti-TIM-3

  • DrugIrinotecanStudies of IrinotecanIrinotecan pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    IV infusion over 90 min on day 1 and 15 of the first 2 cycles. After 2 cycles of treatment, irinotecan may be discontinued at the Investigator's discretion

06

What researchers measure

Primary outcomes

  1. To evaluate the preliminary efficacy of the combinations Sym021+Sym022, Sym021+Sym023 and Sym021+Sym023+irinotecan in patients with BTC or ESCC by assessing overall response rates (ORRs) per Investigator assessment using RECISTv.1.1

    Objective Response Rate (ORR) per Investigator assessment of antitumor activity (based on radiological evidence per RECIST v1.1)

    Time frame: Until disease progression or end of study, whichever comes first, assessed up to 24 months

  2. To evaluate the incidence, severity, and relationship of (S)AEs collected from administration of the first dose of study drug until 30 days after the last dose of the 3 combinations (Sym021+Sym022, Sym021+Sym023 and Sym021+Sym023+irrinotecan)

    Calculation of AE incidence will be based on the number of patients per AE category; AEs in total and sorted by frequency, AEs by relationship, SAEs in total and by relationship, Immune mediated AEs, Fatal AEs

    Time frame: Through study completion up to 30 days after last dose of the three combinations

  3. To evaluate the AEs leading to dose interruption, dose delays, and permanent treatment stop of the 3 combinations (Sym021+Sym022 and Sym021+Sym023 and Sym021+Sym023 +irinotecan)

    Calculation of AE incidence will be based on the number of patients per AE category ; AEs leading to dose interruption, dose delays, and permanent treatment stop

    Time frame: Through study completion up to a maximum of 24 months

Secondary outcomes

  1. Peak plasma (irinotecan) and serum( mAbs) Concentration (Cmax) of the 3 combinations (Sym021+Sym022 and Sym021+Sym023 and Sym021+Sym023+irinotecan)

    Peak serum concentration (Cmax) for each mAbs in each combination.

    Time frame: First study dose and throughout the trial, up to 2 years

  2. Area under the serum concentration versus time curve (AUC) of the 3 combinations (Sym021+Sym022 and Sym021+Sym023 and Sym021+Sym023+ irinotecan)

    Area under the serum concentration versus time curve (AUC) for each mAbs in each combination.

    Time frame: First dose of study drug and throughout the trial, up to 2 years

  3. Time to reach maximum concentration (Tmax) of the 3 combinations (Sym021+Sym022 and Sym021+Sym023 and Sym021+Sym023+irinotecan)

    Time to reach maximum concentration (Tmax) for each mAbs in each combination.

    Time frame: First dose of study drug and throughout the trial, up to 2 years

  4. Trough concentration (Ctrough) of the 3 combinations (Sym021+Sym022 and Sym021+Sym023 and Sym021+Sym023 + irinotecan)

    Trough concentration (Ctrough) for each mAbs in each combination.

    Time frame: First dose of study drug and throughout the trial, up to 2 years

  5. Plasma concentration for irinotecan and its metabolite in the combination Sym021+Sym023+ Irinotecan

    Plasma concentration at the end of infusion for irinotecan and its metabolite in the combination Sym021+Sym023+ Irinotecan

    Time frame: First dose of study drug and throughout the trial, up to 2 years

  6. To confirm the RP2D of each combination

    Confirmation of the RP2D, based on the dose-response relationship (in case more than one dose level is implemented), overall tolerability and safety profile, and the PK and pharmacodynamic data

    Time frame: 36 month

  7. Evaluation of Duration of Response (DOR)

    Duration of the OR will be determined from the day initial response is observed to day of progression is observed. Number and percentages of patients with documented OR will be presented.

    Time frame: Until disease progression or end of study, whichever comes first, assessed up to 24 months

  8. Evaluation of Progression-Free Survival (PFS)

    Will be calculated as from the first study drug dose to the day progression of disease is confirmed radiological or date of death.

    Time frame: From first study drug dose until disease progression or end of study, whichever comes first, assessed up to 24 months

  9. Evaluation of Disease Control Rate (DCR), defined as CR, PR, or stable disease (SD) ≥6 months

    Will be calculated according to standard response criteria

    Time frame: Until disease progression or end of study, whichever comes first, assessed up to 6 months

  10. Evaluation of duration of response.

    Will be calculated from the day the initial response is observed to the day progression of disease is observed

    Time frame: Until disease progression or end of study, whichever comes first, assessed up to 24 months

  11. Evaluation of Objective Response Rate (ORR) per Investigator assessment (based on Immunotherapeutics Response Evaluation Criteria in Solid Tumors [iRECIST])

    Will be based on Investigators assessment on Immunotherapeutic Response Evaluation Criteria in Solid Tumors (iRECIST)

    Time frame: Until disease progression or end of study, whichever comes first, assessed up to 24 months

  12. Evaluation Overall Survival (OS)

    Overall survival will be derived from start of treatment until death or latest survival follow-up.

    Time frame: From first dose of study drug until death or latest survival follow-up assessed up to 30 month

  13. Evaluation of immunogenicity of each antibody drug in the combinations

    Occurrence of antidrug antibody (ADA) measured in serum at selected time points during the study

    Time frame: From screening up to 30 months

07

Study locations

17 sites
  • University of Colorado
    Aurora, Colorado 80045, United States
  • Mayo Clinic - Jacksonville
    Jacksonville, Florida 32224, United States
  • Moffitt Cancer Center
    Tampa, Florida 33612, United States
  • University of Chicago
    Chicago, Illinois 60637-1470, United States
  • University of Kansas Medical Center (KUMC)
    Westwood, Kansas 66205, United States
  • START Midwest
    Grand Rapids, Michigan 49546, United States
  • Mayo Clinic
    Rochester, Minnesota 55902, United States
  • Montefiore Medical Center PRIME
    Bronx, New York 10461, United States
  • Mount Sinai - PRIME
    New York, New York 10029, United States
  • University of Cincinnati Medical Center
    Cincinnati, Ohio 45267, United States
  • MD Anderson
    Houston, Texas 77230, United States
  • Virginia Cancer Specialists, PC
    Fairfax, Virginia 22031, United States
  • Princess Margaret Cancer Centre
    Toronto, Ontario M5G 1X5, Canada
  • Centre Georges-François Leclerc, Department of Medical Oncology
    Dijon, 21000, France
  • Institut de Cancerologie de L'Ouest
    Saint-Herblain, 44805, France
  • Vall d'Hebron Institute of Oncology
    Barcelona, 08035, Spain
  • Hospital Universitario San Carlos
    Madrid, 28040, Spain
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2020 to primary completion in Jun 2024, 43 months.

Of 289 industry-sponsored phase 1 interventional studies under Neoplasm Metastasis, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 75. This study's 43 months is below that.

Counting every sponsor, half of 498 studies reached it within 54 months; a quarter within 33 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 29, 2020
First posted
Nov 24, 2020
StartActual
Oct 12, 2020
Primary completionActual
Jun 3, 2024
CompletionActual
Jun 3, 2024
Last update
Jun 26, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 26, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04641871
Lead sponsor
Symphogen A/S
Responsible party
Sponsor
First posted
Nov 24, 2020
Start date
Oct 12, 2020
Primary completion
Jun 3, 2024
Completion
Jun 3, 2024
Last update
Jun 26, 2024

Study contacts

Nehal Lakhani, MD
principal investigator · START Midwest

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: SYM-023

Start the discussion